emtricitabine

(redirected from Complera)
Also found in: Medical.
Related to Complera: rilpivirine, Stribild

em·tri·cit·a·bine

 (ĕm′trĭ-sĭt′ə-bēn′, -sī′tə-)
n.
An antiviral drug, C8H10FN3O3S, that is a nucleoside reverse transcriptor inhibitor and is used in combination with other drugs to treat HIV infection or to reduce the risk of HIV infection.

[emtri- (probably Em(ory) University, where the drug was discovered + Tri(angle) Pharmaceuticals, company to which it was licensed) + -citabine, nucleoside analog antiviral and anticancer drug suff.; see zalcitabine.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
Translations

emtricitabine

n emtricitabina
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
Individual factors linked to lower or higher bone density at the femoral neck Individual factors linked to lower Individual factors linked to (worse) bone density at femoral neck higher (better) bone density at femoral neck Being a woman Higher body mass index Longer treatment with tenofovir (TDF, Longer treatment with an Viread) * for HIV integrase inhibitor for HIV Older age Hypogonadism or postmenopausal status ([dagger]) No physical activity Low vitamin D AIDS wasting in the past Hepatitis C virus (HCV) infection * Tenofovir disoproxil fumarate (TDF) is part of the combination drugs Atripla, Complera, Stribild, and Truvada.
NNRTI regimens Complera RPV-TDF-FTC (or RPV plus RPV not recommended with a two-NRTI backbone) pretreatment HIV RNA > 100,000 copies-mL or CD4 cell count < 200 cells- mm3.
Both firms signed an original agreement in 2009 to develop and commercialise Complera, marketed as Eviplera, which combines tenofovir disoproxil fumarate, emtricitabine and rilpivirine in a once-daily tablet.
* Complera (Rilpivirine/Tenofovir/FTC), approved in August 2011
In the agency's view, Gilead's recent approval of HIV therapy Complera as well as its FDA filing for another such therapy, Quad, should cement its presence in the global HIV drug market.
The pharmaceutical dosage form used in this study was Complera procured from the local market and labelled to contain 200 mg of emtricitabine, 300 mg of tenofovir disoproxil fumarate, and 25 mg of rilpivirine per tablet.
M2 EQUITYBITES-December 16, 2013-Gilead's once-daily single tablet HIV-1 regimen Complera receives US FDA approval
M2 PHARMA-December 16, 2013-Gilead's once-daily single tablet HIV-1 regimen Complera receives US FDA approval
Stribild is the third HIV combination medication developed by Gilead, following Atripla in 2006 and Complera in 2011.